Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vagistat-1 is first OTC one-day vaginal yeast infection treatment.

This article was originally published in The Tan Sheet

Executive Summary

BRISTOL-MYERS SQUIBB VAGISTAT-1 ONE-DAY OTC VAGINAL YEAST INFECTION TREATMENT to launch by spring in drug, food and mass market merchandisers. BMS received approval for the OTC 6.5% tioconazole vaginal yeast infection ointment on Feb. 11. The company filed a supplemental NDA (20-676) for U.S. OTC use of tioconazole for vaginal yeast infections in November 1995. Vagistat-1 has been approved for OTC marketing in the U.K. since January 1994.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086711

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel